Literature DB >> 12744473

Changing patterns in the neuropathogenesis of HIV during the HAART era.

T D Langford1, S L Letendre, G J Larrea, E Masliah.   

Abstract

Rapid progress in the development of highly active antiretroviral therapy has changed the observed patterns in HIV encephalitis and AIDS-related CNS opportunistic infections. Early in the AIDS epidemic, autopsy studies pointed to a high prevalence of these conditions. With the advent of nucleoside reverse transcriptase inhibitors, the prevalence at autopsy of opportunistic infections, such as toxoplasmosis and progressive multifocal leukoencephalopathy, declined while that of HIV encephalitis increased. After the introduction of protease inhibitors, a decline in both HIV encephalitis and CNS opportunistic infections was observed. However, with the increasing resistance of HIV strains to antiretrovirals, there has been a resurgence in the frequency of HIV encephalitis and HIV leukoencephalopathy. HIV leukoencephalopathy in AIDS patients failing highly active antiretroviral therapy is characterized by massive infiltration of HIV infected monocytes/macrophages into the brain and extensive white matter destruction. This condition may be attributable to interactions of anti-retrovirals with cerebrovascular endothelium, astroglial cells and white matter of the brain. These interactions may lead to cerebral ischemia, increased blood-brain barrier permeability and demyelination. Potential mechanisms of such interactions include alterations in host cell signaling that may result in trophic factor dysregulation and mitochondrial injury. We conclude that despite the initial success of combined anti-retroviral therapy, more severe forms of HIV encephalitis appear to be emerging as the epidemic matures. Factors that may contribute to this worsening include the prolonged survival of HIV-infected patients, thereby prolonging the brain's exposure to HIV virions and proteins, the use of increasingly toxic combinations of poorly penetrating drugs in highly antiretroviral-experienced AIDS patients, and selection of more virulent HIV strains with higher replication rates and greater virulence in neural tissues.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12744473      PMCID: PMC4842209          DOI: 10.1111/j.1750-3639.2003.tb00019.x

Source DB:  PubMed          Journal:  Brain Pathol        ISSN: 1015-6305            Impact factor:   6.508


  123 in total

1.  Cellular factors involved in the induction of resistance of HIV to antiretroviral agents.

Authors:  O Turriziani; G Antonelli; F Dianzani
Journal:  Int J Antimicrob Agents       Date:  2000-11       Impact factor: 5.283

Review 2.  Functional expression and localization of P-glycoprotein at the blood brain barrier.

Authors:  Reina Bendayan; Gloria Lee; Moise Bendayan
Journal:  Microsc Res Tech       Date:  2002-06-01       Impact factor: 2.769

3.  Ritonavir increases the level of active ADD-1/SREBP-1 protein during adipogenesis.

Authors:  A T Nguyen; A Gagnon; J B Angel; A Sorisky
Journal:  AIDS       Date:  2000-11-10       Impact factor: 4.177

4.  Pharmacokinetics and bioavailability of zidovudine in humans.

Authors:  M R Blum; S H Liao; S S Good; P de Miranda
Journal:  Am J Med       Date:  1988-08-29       Impact factor: 4.965

5.  HIV-1 reverse transcriptase sequence in plasma and cerebrospinal fluid of patients with AIDS dementia complex treated with Abacavir.

Authors:  E R Lanier; G Sturge; D McClernon; S Brown; M Halman; N Sacktor; J McArthur; J H Atkinson; D Clifford; R W Price; D Simpson; G Torres; J Catalan; K Marder; C Power; C Hall; C Romero; B Brew
Journal:  AIDS       Date:  2001-04-13       Impact factor: 4.177

6.  Mitochondrial involvement in antiretroviral therapy-related lipodystrophy.

Authors:  M G Zaera; O Miró; E Pedrol; A Soler; M Picón; F Cardellach; J Casademont; V Nunes
Journal:  AIDS       Date:  2001-09-07       Impact factor: 4.177

7.  Changes in mitochondrial DNA as a marker of nucleoside toxicity in HIV-infected patients.

Authors:  Hélène C F Côté; Zabrina L Brumme; Kevin J P Craib; Christopher S Alexander; Brian Wynhoven; Lillian Ting; Hubert Wong; Marianne Harris; P Richard Harrigan; Michael V O'Shaughnessy; Julio S G Montaner
Journal:  N Engl J Med       Date:  2002-03-14       Impact factor: 91.245

8.  Brain viral burden in HIV infection.

Authors:  C L Achim; R Wang; D K Miners; C A Wiley
Journal:  J Neuropathol Exp Neurol       Date:  1994-05       Impact factor: 3.685

9.  Interleukin-8 as a macrophage-derived mediator of angiogenesis.

Authors:  A E Koch; P J Polverini; S L Kunkel; L A Harlow; L A DiPietro; V M Elner; S G Elner; R M Strieter
Journal:  Science       Date:  1992-12-11       Impact factor: 47.728

10.  The effect of cholesterol-lowering and antioxidant therapy on endothelium-dependent coronary vasomotion.

Authors:  T J Anderson; I T Meredith; A C Yeung; B Frei; A P Selwyn; P Ganz
Journal:  N Engl J Med       Date:  1995-02-23       Impact factor: 91.245

View more
  76 in total

1.  Neuropsychological evaluation and follow up in jcv- and non-jcv-related leukoencephalopathies in HIV infection.

Authors:  C Zucchella; E Sinforiani; E Tavazzi; S Del Bue; S Novati; R Maserati; M Ceroni; S Bastianello; L Minoli; P Ferrante; E Marchioni
Journal:  Neurol Sci       Date:  2011-06-01       Impact factor: 3.307

2.  Novel p75 neurotrophin receptor ligand stabilizes neuronal calcium, preserves mitochondrial movement and protects against HIV associated neuropathogenesis.

Authors:  Rick B Meeker; Winona Poulton; Gillian Clary; Michael Schriver; Frank M Longo
Journal:  Exp Neurol       Date:  2015-09-28       Impact factor: 5.330

3.  Cliniconeuropathologic correlates of human immunodeficiency virus in the era of antiretroviral therapy.

Authors:  I Everall; F Vaida; N Khanlou; D Lazzaretto; C Achim; S Letendre; D Moore; R Ellis; M Cherner; B Gelman; S Morgello; E Singer; I Grant; E Masliah
Journal:  J Neurovirol       Date:  2009-09       Impact factor: 2.643

4.  HIV proviral DNA associated with decreased neuropsychological function.

Authors:  Bruce Shiramizu; Robert Paul; Andrew Williams; Cecilia Shikuma; Michael Watters; John Grove; Victor Valcour
Journal:  J Neuropsychiatry Clin Neurosci       Date:  2007       Impact factor: 2.198

5.  Relationship of antiretroviral treatment to postmortem brain tissue viral load in human immunodeficiency virus-infected patients.

Authors:  Dianne Langford; Jennifer Marquie-Beck; Sergio de Almeida; Deborah Lazzaretto; Scott Letendre; Igor Grant; J Allen McCutchan; Eliezer Masliah; Ronald J Ellis
Journal:  J Neurovirol       Date:  2006-04       Impact factor: 2.643

6.  Regional cortical thinning associated with detectable levels of HIV DNA.

Authors:  Kalpana J Kallianpur; Gregory R Kirk; Napapon Sailasuta; Victor Valcour; Bruce Shiramizu; Beau K Nakamoto; Cecilia Shikuma
Journal:  Cereb Cortex       Date:  2011-10-19       Impact factor: 5.357

7.  Transcriptome analysis of HIV-infected peripheral blood monocytes: gene transcripts and networks associated with neurocognitive functioning.

Authors:  Andrew J Levine; Steve Horvath; Eric N Miller; Elyse J Singer; Paul Shapshak; Gayle C Baldwin; Otoniel Martínez-Maza; Mallory D Witt; Peter Langfelder
Journal:  J Neuroimmunol       Date:  2013-09-26       Impact factor: 3.478

Review 8.  HIV's double strike at the brain: neuronal toxicity and compromised neurogenesis.

Authors:  Marcus Kaul
Journal:  Front Biosci       Date:  2008-01-01

9.  Disrupted brain networks in the aging HIV+ population.

Authors:  Neda Jahanshad; Victor G Valcour; Talia M Nir; Omid Kohannim; Edgar Busovaca; Krista Nicolas; Paul M Thompson
Journal:  Brain Connect       Date:  2012

10.  HIV-1 clade-specific differences in the induction of neuropathogenesis.

Authors:  Vasudev R Rao; Andrew R Sas; Eliseo A Eugenin; Nagadenahalli B Siddappa; Heather Bimonte-Nelson; Joan W Berman; Udaykumar Ranga; William R Tyor; Vinayaka R Prasad
Journal:  J Neurosci       Date:  2008-10-01       Impact factor: 6.167

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.